Comparative Pharmacology
Head-to-head clinical analysis: AZEDRA versus THALLOUS CHLORIDE TL 201.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZEDRA versus THALLOUS CHLORIDE TL 201.
AZEDRA vs THALLOUS CHLORIDE TL 201
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iobenguane is taken up by adrenergic tissues via the norepinephrine transporter and accumulates in cells of the adrenal medulla and pheochromocytoma/paraganglioma tumors. Its guanidinoethyl group inhibits catecholamine uptake, but the primary therapeutic effect is from the beta emission of I-131, causing DNA damage and cell death.
Thallous chloride Tl-201 is a potassium analog that is taken up by viable myocardial cells via the Na+/K+ ATPase pump. Its distribution reflects regional myocardial blood flow and cell viability. In areas of ischemia or infarction, uptake is reduced, creating a perusion defect.
Intravenous infusion of iobenguane I-131 at 3.7 MBq/kg (0.1 mCi/kg) for diagnostic imaging; treatment dose is 296 MBq/kg (8 mCi/kg) up to a maximum of 22.2 GBq (600 mCi) administered intravenously over 30-60 minutes every 12-16 weeks for up to 4 cycles.
111-148 MBq (3-4 mCi) intravenous injection for myocardial perfusion imaging; imaging begins 5-10 minutes post-injection.
None Documented
None Documented
The terminal elimination half-life of AZEDRA (iobenguane I-131) ranges from 30 to 40 hours (mean approximately 35 hours) based on total radioactivity. The effective half-life, accounting for both physical decay of I-131 (8.02 days) and biological elimination, is approximately 24-50 hours. This informs the duration of radiation safety precautions and tumor dose delivery.
Terminal elimination half-life: approximately 73 hours. Clinical context: The long half-life allows for delayed imaging (e.g., redistribution imaging for thallium-201 myocardial perfusion scans).
Renal excretion of intact drug and metabolites accounts for approximately 90% of administered radioactivity within 96 hours; the remainder is eliminated via feces (approximately 10%). The major route is renal, with about 40-50% excreted unchanged.
Renal: approximately 70% over 10 days; fecal: less than 30% over 10 days.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical